Date: 01st November, 2026

To

The Manager **BSE Limited** **P. J. Towers, Dalal Street** **Mumbai-400001** **(BSE Scrip Code: 544742)**	**The Manager** **NSE Limited** **Exchange Plaza, Bandra Kurla Complex,** **Bandra (E), Mumbai- 400051.** **(NSE Symbol: SAIPARENT)**

Unit: Sai Parenteral's Limited

Sub: Outcome of Board Meeting held on Sunday, 01st November, 2026.

***

With reference to the subject cited, this is to inform the Exchanges that the Board Meeting of Sai Parenteral's Limited held on Sunday, the 01st day of November, 2026 at 12:30 p.m. at the Registered Office of the Company considered and approved the following:

1. Un-audited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.

2. Limited Review Reports (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.

3. Acquisition of the remaining 25% equity shareholding in M/s. SP Analytics Private Limited, a subsidiary of the Company in which the company holds 75%, thereby making it a wholly owned subsidiary of the Company. ***(Details are attached as Annexure A)***

4. Constitution of Management Committee for smooth functioning and administration convenience of the Company. ***(Details are attached as Annexure B)***

5. Pursuant to the approval of the Board of Directors of the Company at its meeting held on August 11, 2026, the Company has completed the acquisition of 60% of the equity share capital of Saicriti Pharma Private Limited. Consequent to the aforesaid acquisition, Saicriti Pharma Private Limited has become a subsidiary of the Company with effect from the date of completion of the acquisition.

The Meeting concluded at 2:30 p.m.

This is for the information and records of the Exchanges, please.

Thanking you.
Yours sincerely,
For Sai Parenterals Limited

ANIL KUMAR KARUSALA
Digitally signed by ANIL KUMAR KARUSALA
Date: 2026.11.01 15:56:47 +05'30'

Anil Kumar Karusala
Managing Director
(DIN- 01866646)

Annexure – A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026]

Name of the Target Entity	**M/s. SP Analytics Private Limited**
Details in brief such as size, turnover etc	Nil
Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The acquisition falls within the ambit of Related Party Transactions (RPTs) under the applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as the entity being acquired is a related party of the Company. Further, the Promoter(s)/Promoter Group have an interest in the entity being acquired by virtue of their relationship with the said entity. The transaction is proposed to be undertaken at arm's length, based on the terms and conditions mutually agreed upon by the parties and duly supported by an appropriate assessment, wherever applicable.
Industry to which the entity being acquired belongs	Pharma Sector
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Acquisition of the remaining 25% equity shareholding in M/s. SP Analytics Private Limited, a subsidiary of the Company in which the company holds 75%, thereby making it a wholly owned subsidiary of the Company.
Brief Details of any governmental or regulatory approvals required for the acquisition	Not required
Indicative Time period for completion of the acquisition	On or before 31.12.2026

Consideration - whether cash consideration or share swap or any other form and details of the same	Cash
Cost of acquisition and/or the price at which the shares are acquired	Acquisition of 2,500 equity shares of face value Rs.10/- each, aggregating to Rs.25,000/-.
Percentage of shareholding / control acquired and / or number of shares acquired	Acquisition of the remaining 25% equity shareholding in M/s. SP Analytics Private Limited, a subsidiary of the Company in which the company holds 75%, thereby making it a wholly owned subsidiary of the Company.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	M/s. S P Analytics Private Limited was incorporated on November 16, 2023, with the main object of undertaking testing, analysis and examination of pharmaceuticals, medicines, drugs and other related materials. The Company has reported nil turnover during the last three financial years.

Annexure – B

MANAGEMENT COMMITTEE

S. No	Name	Designation	Category
1.	Anil Kumar Karusala	Managing Director	Chairman
2.	Vijitha Gorrepati	Whole Time Director	Member
3.	Kunal Kakumanu	Executive Director	Member
4.	Arvind Gannimitta	Chief Operating Officer	Member
5.	Ashwani Singh Bisht	Company Secretary & Compliance Officer	Member

SAI PARENTERAL'S LIMITED

Regd. Off.: Plot No 39, 5th Floor Lavanya Arcade. Jayabheri Enclave, Gachibowli, Seri Lingampally, Telangana, India - 500032
CIN:U24231TG2001PLC036043 , Web: www.saiparenterals.com, Email: CS@saiparenterals.com,Phone: +91 7997991301

Unaudited Consolidated Financial Results For The Quarter And Half Year Ended On 30th September, 2026

(₹ in Millions)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Financial Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Audited
I	**Income**						
	a. Revenue from Operations	1,949.18	1,786.72	535.28	3,735.90	869.18	3,809.98
	b. Other income	37.19	37.41	13.35	74.60	25.09	85.20
	Total Income	**1,986.37**	**1,824.13**	**548.63**	**3,810.50**	**894.27**	**3,895.18**
II	**Expenses**						
	a. Cost of materials consumed	822.44	1,161.23	400.38	1,983.66	652.26	2,381.12
	b. Purchases of stock in trade	-					
	c. Change in inventories of finished goods, work-in-progress and stock-in-trade	207.63	(98.97)	(52.86)	108.66	(86.12)	41.11
	d. Employees benefits expense	128.55	115.42	35.99	243.97	68.53	292.81
	e. Finance costs	89.82	93.60	21.67	183.42	46.31	184.38
	f. Depreciation and amortisation expense	250.90	81.10	14.36	332.00	28.85	168.52
	g. Other Expenses	388.14	373.86	37.55	762.00	72.85	707.96
	Total Expenses	**1,887.48**	**1,726.23**	**457.09**	**3,613.71**	**782.68**	**3,775.90**
III	**Profit/(Loss) before Exceptional Items & Tax (I-II)**	**98.89**	**97.90**	**91.54**	**196.79**	**111.59**	**119.28**
IV	Exceptional Items (Refer Note No.3)	-					
V	**Profit/(Loss) before Tax (III-IV)**	**98.89**	**97.90**	**91.54**	**196.79**	**111.59**	**119.28**
VI	Tax expense:						
	Current tax	16.15	41.72	28.04	57.86	31.54	49.34
	Deferred tax	(22.36)	(23.05)		(45.41)	2.40	(72.65)
	Earlier Years	-	-	-			
VII	**Profit/(Loss) after tax**	**105.10**	**79.23**	**63.50**	**184.33**	**77.64**	**142.59**
	Share in Profit/(Loss) after tax in Associate Company	-	-	-		-	
	Profit After Tax including Share in Associate Company	**105.10**	**79.23**	**63.50**	**184.33**	**77.64**	**142.59**
VIII	**Other Comprehensive Income/(Loss)**						
A.(i)	Items that will not be reclassified to profit or loss	-					
(ii)	Income Tax on Items that will not be reclassified to profit or loss	-					
B.(i)	Items that will be reclassified to profit or loss	-					
(ii)	Income Tax on Items that will be reclassified to profit or loss	-					
	Total Other Comprehensive Income/(Loss) (Net of Tax)	**-**	**-**	**-**	**-**	**-**	**-**
IX	**Total Comprehensive Income for the period (VII+VIII)**	**105.10**	**79.23**	**63.50**	**184.33**	**77.64**	**142.59**
X	Paid-up Equity Share Capital (Face Value of ₹ 10 per Share)						
XI	Other Equity						
XII	Earning per Equity Share (Refer Note no. 6)						
	(1) Basic EPS before exceptional items	2.38	1.79	0.48	4.17	2.82	4.36
	(2) Basic EPS after exceptional items	2.38	1.79	0.48	4.17	2.82	4.36
	(3) Diluted EPS before exceptional items	2.38	1.79	0.48	4.17	2.82	4.36
	(4) Diluted EPS after exceptional items	2.38	1.79	0.48	4.17	2.82	4.36

Notes:-

1 Results are prepared under Regulation 33 of the SEBI (LODR) Regulations, 2015 and applicable Ind AS under Section 133 of the Companies Act, 2013. Reviewed by the Audit Committee and approved by the Board on 01 November 2026. Statutory Auditors carried out a Limited Review and issued an unmodified conclusion.

2 Earnings Per Share (EPS) for the quarters ended has not been annualised, except for the quarter/year ended 31st March 2026.

3 Per Ind AS 108, the CODM evaluates performance on the basis of a single reportable segment (branded generic formulations and CDMO products and services, domestic and international). No segment-wise disclosure is provided.

4 No exceptional and/or extraordinary items were reported during the quarter ended 30 september 2026.

Date : 01-11-2026
Place : Hyderabad

SAI PARENTERALS LIMITED HYDERABAD

For Sai Parenteral's Limited

(Anil Kumar Karusala)
Chairman
DIN: 01866646

SAI PARENTERAL'S LIMITED

Regd. Off.: Plot No 39, 5th Floor Lavanya Arcade, Jayabheri Enclave, Gachibowli, Seri Lingampally, Telangana, India - 500032
CIN:U24231TG2001PLC036043 , Web: www.saiparenterals.com, Email: CS@saiparenterals.com,Phone: +91 7997991301

Unaudited Consolidated Financial Results For The Quarter And Half Year Ended On 30th September, 2026

(₹ in Millions)

Sr. No.	Particulars	As at 30.09.2026 Unaudited	As at 31.03.2026 Audited
	ASSETS		
1	**Non-Current Assets**		
	(a) Property, plant and equipment	825.82	616.08
	(b) Right of Use Assets	1,255.35	1,295.28
	(c) Capital work-in progress	2,692.70	2,122.05
	(d) Intangible assets	497.52	479.14
	(e) Goodwill on consolidation	1,189.30	1,246.27
	(f) Financial assets		
	(i) Other financial assets	63.58	21.29
	(ii) Loan and advances	39.86	-
	(g) Deferred Tax Assets (net)	126.98	81.15
	(h) Other non current assets	157.30	161.22
	(i) Non-Current Investment	0.06	-
	Total Non Current Assets	**6,848**	**6,022**
2	**Current Assets**		
	(a) Inventories	1,822.04	1,718.14
	(b) Financial Assets	-	
	(i) Trade receivables	2,545.25	1,810.33
	(ii) Cash and cash equivalents	1,293.30	4,169.66
	(iii) Loans and advances	59.46	26.07
	(iv) Other financial assets	192.45	170.60
	(c) Other current assets	437.10	325.00
	Total Current Assets	**6,349.59**	**8,219.80**
	Total Assets	**13,198.08**	**14,242.29**
	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	3,121.15	220.90
	(b) Equity Attributable to Parent	1,836.70	4,686.83
	(c) Non-controlling Interest	123.19	43.54
	Total Equity	**5,081.03**	**4,951.26**
	Liabilities		
1	**Non-Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	812.14	904.12
	(ii) Other Financial Liabilities	-	
	(iii) Lease Liabilities	1,305.80	1,354.88
	(b) Provisions	14.74	7.51
	(c) Deferred Tax Liabilities (net)	4.19	-
	(d) Other Non-current Liabilities	1,339.20	1,298.20
	Total Non-Current Liabilities	**3,476.08**	**3,564.71**
2	**Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	2,754.28	2,290.73
	(ii) Trade payables		-
	(A) Total outstanding dues of micro enterprises and small enterprises	115.58	244.62
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,158.42	1,241.47
	(iii) Other financial liabilties	48.01	1,179.42
	(iv) Lease Liabilities	174.10	138.35
	(b) Other current liabilities	202.90	473.29
	(c) Provisions	187.68	158.44
	(d) Current Tax Liabilities (Net)	-	
	Total Current Liabilities	**4,640.97**	**5,726.31**
	Total Equity and Liabilities	**13,198.07**	**14,242.29**

Date : 01-11-2026

Place : Hyderabad

For Sai Parenteral's Limited

SAI PARENTERALS LIMITED HYDERABAD

(Anil Kumar Karusala)
Chairman
DIN: 01866646

SAI PARENTERAL'S LIMITED

Regd. Off.: Plot No 39, 5th Floor Lavanya Arcade, Jayabheri Enclave, Gachibowli, Seri Lingampally, Telangana, India - 500032
CIN:U24231TG2001PLC036043 , Web: www.saiparenterals.com, Email: CS@saiparenterals.com,Phone: +91 7997991301

Unaudited Consolidated Cash Flow Statement for Half Year Ended On 30th September, 2026

(₹ in Millions)

Sr. No.	Particulars	As at 30.09.2026 Unaudited	As at 30.09.2025 Audited
A	**Cash Flow from Operating Activities**		
	Net Profit Before Tax	**196.79**	**111.59**
	Adjustments for :-		
	Interest income		
	Loss on sale of Property, Plant and Equipments		
	Depreciation and amortisation	163.20	28.85
	Finance charges	183.42	46.31
	Foreign exchange fluctuation	39.43	(6.78)
	Gratuity Expense	-	0.57
	Sundry debtors written off	-	0.00
	Less:		
	Sundry balances written back	-	-
	Interest income	(50.94)	(0.93)
	Operating Profit before working capital changes	**531.90**	**179.60**
	Movements in Working Capital :-		
	(Increase) / Decrease in Inventories	(74.85)	(225.16)
	(Increase) / Decrease in other financial assets	(21.85)	(14.83)
	(Increase) / Decrease in other current assets	(111.17)	(126.82)
	(Increase) / Decrease in Trade & other receivables	(734.92)	(244.76)
	(Increase) / Decrease in loans and advances	17.31	(251.53)
	Increase / (Decrease) in other financial liabilities	(1131.41)	19.22
	Increase / (Decrease) in other current liabilities	(252.77)	(5.82)
	Increase / (Decrease) in Trade payables & Other liabilities	(216.67)	83.54
	Increase / (Decrease) in provisions	(18.56)	(7.89)
	Cash Generated from Operations	**(2012.98)**	**(594.45)**
	Taxes Paid / (Refund) (Net)	(41.62)	(65.67)
	Net Cash Inflow / (Out Flow) from Operating Activities	**(2054.60)**	(660.12)
B	**Cash Flow from Investing Activities**		
	Sale/(Purchase) of property, plant and equipment	(204.77)	(20.78)
	Decrease/ (Increase) in CWIP	(291.66)	(13.17)
	Decrease/ (Increase) in Intangible Assets	(18.38)	(0.36)
	Decrease/ (Increase) in Financial Assets	(238.44)	(0.18)
	Decrease/(Increase) in Other Non Current Assets	3.92	(14.45)
	Interest Received	50.94	0.93
	Net Cash Inflow / (Outflow) from Investing Activities	**(698.38)**	**(48.01)**
C	**Cash Flow from Financing Activities**		
	Proceeds/(repayment) of short term borrowings (net)	110.83	(231.23)
	Proceeds/(repayment) of long term borrowings (net)	15.89	52.38
	Finance cost	(178.81)	(46.31)
	Proceeds from issue of equity shares	-	51.45
	Proceeds from security premium on issue of shares	(38.51)	1000.94
	Proceeds/(repayment) of other financial liability	(32.77)	14.24
	Net Cash Inflow / (Out Flow) from Financing Activities	**(123.38)**	**841.47**
	Net Increase/(Decrease) in Cash & Cash equivalents	(2876.36)	133.34
	Cash and Cash Equivalents at the Beginning	4169.66	20.86
	Cash and Cash Equivalents at the End	1293.30	154.20

Date : 01-11-2026

Place : Hyderabad

For Sai Parenteral's Limited

SAI PARENTERALS LIMITED HYDERABAD

(Anil Kumar Karusala)
Chairman
DIN: 01866646

SAI PARENTERAL'S LIMITED

Regd. Off.: Plot No 39, 5th Floor Lavanya Arcade, Jayabheri Enclave, Gachibowli, Seri Lingampally, Telangana, India - 500032
CIN:U24231TG2001PLC036043 , Web: www.saiparenterals.com, Email: CS@saiparenterals.com,Phone: +91 7997991301

Unaudited Standalone Financial Results For The Quarter And Half Year Ended On 30th September, 2026

(₹ in Millions)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Financial Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Audited
I	**Income**						
	a. Revenue from Operations	529.09	527.79	477.79	1,056.87	669.80	1,622.52
	b. Other income	35.92	34.14	6.26	70.06	18.68	27.40
	Total Income	**565.01**	**561.92**	**484.05**	**1,126.93**	**688.48**	**1,649.93**
II	**Expenses**						
	a. Cost of materials consumed	193.52	400.49	410.83	594.01	551.71	1,058.92
	b. Purchases of stock in trade						
	c. Change in inventories of finished goods, work-in-progress and stock-in-trade	164.26	(59.48)	(99.03)	104.78	(132.91)	(16.91)
	d. Employees benefits expense	36.78	33.40	30.50	70.18	58.02	142.99
	e. Finance costs	24.86	35.74	14.72	60.60	32.30	87.70
	f. Depreciation and amortisation expense	15.22	13.63	13.36	28.85	26.54	57.83
	g. Other Expenses	43.39	19.84	31.97	63.24	59.27	131.72
	Total Expenses	**478.04**	**443.62**	**402.34**	**921.66**	**594.93**	**1,462.24**
III	**Profit/(Loss) before Exceptional Items & Tax (I-II)**	**86.97**	**118.30**	**81.71**	**205.27**	**93.63**	**187.69**
IV	Exceptional Items (Refer Note No.3)	-					
V	**Profit/(Loss) before Tax (III-IV)**	**86.97**	**118.30**	**81.71**	**205.27**	**93.63**	**187.69**
VI	Tax expense:						
	Current tax	22.99	25.81	25.32	48.79	26.85	29.73
	Deferred tax	(0.87)	3.74		2.88	2.14	(9.81)
	Earlier Years	-	-	-			
VII	**Profit/(Loss) after tax**	**64.86**	**88.75**	**56.39**	**153.61**	**64.64**	**167.76**
	Share in Profit/(Loss) after tax in Associate Company	-	-	-		-	
	Profit After Tax including Share in Associate Company	**64.86**	**88.75**	**56.39**	**153.61**	**64.64**	**167.76**
VIII	**Other Comprehensive Income/(Loss)**						
A.(i)	Items that will not be reclassified to profit or loss	-				0.50	
(ii)	Income Tax on Items that will not be reclassified to profit or loss	-					
B.(i)	Items that will be reclassified to profit or loss	-					
(ii)	Income Tax on Items that will be reclassified to profit or loss	-					
	Total Other Comprehensive Income/(Loss) (Net of Tax)	-	-	-	-	**0.50**	-
IX	**Total Comprehensive Income for the period (VII+VIII)**	**64.86**	**88.75**	**56.39**	**153.61**	**65.14**	**167.76**
X	Paid-up Equity Share Capital (Face Value of ₹ 10 per Share)						
XI	Other Equity						
XII	Earning per Equity Share (Refer Note no. 6)						
	(1) Basic EPS before exceptional items	1.47	2.01	0.42	3.48	2.35	5.13
	(2) Basic EPS after exceptional items	1.47	2.01	0.42	3.48	2.35	5.13
	(3) Diluted EPS before exceptional items	1.47	2.01	0.42	3.48	2.35	5.13
	(4) Diluted EPS after exceptional items	1.47	2.01	0.42	3.48	2.35	5.13

Notes:-

1 Results are prepared under Regulation 33 of the SEBI (LODR) Regulations, 2015 and applicable Ind AS under Section 133 of the Companies Act, 2013. Reviewed by the Audit Committee and approved by the Board on 01 November 2026. Statutory Auditors carried out a Limited Review and issued an unmodified conclusion.

2 Earnings Per Share (EPS) for the quarters ended has not been annualised, except for the quarter/year ended 31st March 2026.

3 Per Ind AS 108, the CODM evaluates performance on the basis of a single reportable segment (branded generic formulations and CDMO products and services, domestic and international). No segment-wise disclosure is provided.

4 No exceptional and/or extraordinary items were reported during the quarter ended 30 September 2026.

Date : 01-11-2026
Place : Hyderabad

SAI PARENTERALS LIMITED HYDERABAD

for Sai Parenteral's Limited

(Anil Kumar Karusala)
Chairman
DIN: 01866646

SAI PARENTERAL'S LIMITED

Regd. Off.: Plot No 39, 5th Floor Lavanya Arcade, Jayabheri Enclave, Gachibowli, Seri Lingampally, Telangana, India - 500032
CIN:U24231TG2001PLC036043 , Web: www.saiparenterals.com, Email: CS@saiparenterals.com,Phone: +91 7997991301

Unaudited Standalone Statement of Assets and Liabilities as on 30th September, 2026

(₹ in Millions)

Sr. No.	Particulars	As at 30.09.2026 Unaudited	As at 31.03.2026 Audited
	ASSETS		
1	**Non-Current Assets**		
	(a) Property, plant and equipment	467.64	402.45
	(b)ROU	16.85	19.28
	(c) Capital work-in progress	8.14	10.93
	(d) Intangible assets	5.01	5.50
	(e) Intangible assets under development	-	-
	(f) Financial assets	-	-
	(i) Other financial assets	248.69	113.85
	(g) Deferred Tax Assets (net)	6.76	9.64
	(h) Other non current assets	132.35	31.75
	(h) Non-Current Investment	1,739.07	1,577.07
	Total Non-Current Assets	**2,624.52**	**2,170.46**
2	**Current Assets**		
	(a) Inventories	644.78	595.01
	(b) Financial Assets	-	
	(i) Trade receivables	1,462.00	812.18
	(ii) Cash and cash equivalents	1,236.84	4,102.81
	(iii) Loans and advances	106.62	17.31
	(iv) Other financial assets	149.68	133.99
	(d) Other current assets	133.37	208.03
	Total Current Assets	**3,733.29**	**5,869.34**
	Total Assets	**6,357.81**	**8,039.79**
	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	220.90	220.90
	(b) Equity Attributable to Parent	4,784.16	4,648.94
	Total Equity	**5,005.06**	**4,869.84**
	Liabilities		
1	**Non-Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	379.01	422.31
	(ii) Other Financial Liabilities	13.47	14.80
	(b) Provisions	5.10	4.93
	(c) Deferred Tax Liabilities (net)	-	-
	(d) Other Non-current Liabilities	-	-
	Total Non-Current Liabilities	**397.59**	**442.04**
2	**Current Liabilities**		
	(a) Financial Liabilities		
	(i) Borrowings	632.35	909.75
	(ii) Trade payables		
	(A) Total outstanding dues of micro enterprises and small enterprises	99.48	181.89
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	77.94	73.36
	(iii) Other financial liabilties	39.99	1,183.12
	(b) Other current liabilities	25.13	312.26
	(c) Provisions	80.28	67.53
	(d) Current Tax Liabilities (Net)	-	
	Total Current Liabilities	**955.17**	**2,727.91**
	Total Equity and Liabilities	**6,357.80**	**8,039.79**

Date : 01-11-2026

Place : Hyderabad

SAI PARENTERALS LIMITED HYDERABAD
For Sai Parenterals Limited
(Anil Kumar Karusala)

SAI PARENTERAL'S LIMITED

Regd. Off.: Plot No 39, 5th Floor Lavanya Arcade, Jayabheri Enclave, Gachibowli, Seri Lingampally, Telangana, India - 500032
CIN:U24231TG2001PLC036043 , Web: www.saiparenterals.com, Email: CS@saiparenterals.com,Phone: +91 7997991301

Unaudited Standalone Cash Flow Statement as on 30th September, 2026

(₹ in Millions)

Sr. No.	Particulars	As at 30.09.2026 Unaudited	As at 30.09.2025 Audited
A	**Cash Flow from Operating Activities**		
	Net Profit Before Tax	**205.27**	**111.59**
	Adjustments for :-		
	Depreciation and amortization expense	28.85	28.85
	Finance cost	60.60	46.31
	Fair valuation of invesments in mutual fund	-	
	Foreign exchange fluctuation	(2.26)	(6.78)
	Gratuity Expense	0.17	0.57
	Sundry debtors written off	-	
	Discount allowed	-	
	Less:		
	Discounts received	-	
	Non Operating Income due to Prior Period Items	-	
	Sundry balances written back	-	
	Interest income	(56.33)	(0.93)
	Profit on sale of property ,plaant & equipement	(1.67)	
	Discounts received	-	
	Operating Profit before working capital changes	**234.63**	**179.60**
	Movements in Working Capital :-		
	(Increase)/Decrease in trade receivables	(649.82)	(244.76)
	(Increase)/Decrease in inventories	(49.76)	(225.16)
	(Increase)/Decrease in other financial assets	(15.69)	(14.83)
	(Increase)/Decrease in other current assets	74.66	(126.82)
	Increase / (Decrease) in trade payables	(77.84)	83.54
	(Increase) / Decrease in loans and advances	(89.31)	(251.53)
	Increase / (Decrease) in other financial liabilities	(1,141.58)	19.22
	Increase / (Decrease) in other current liabilities	(288.19)	(5.82)
	Increase / (Decrease) in liabilities for provisions and current tax	(0.54)	(7.89)
	Cash Generated from Operations	**(2,003.45)**	**(594.45)**
	Taxes Paid / (Refund) (Net)	(36.04)	(65.67)
	Net Cash Inflow / (Out Flow) from Operating Activities	**(2,039.49)**	**(660.11)**
B	**Cash Flow from Investing Activities**		
	Sale/(Purchase) of property, plant and equipment	(89.06)	(20.78)
	Decrease/ (Increase) in CWIP	2.78	(13.17)
	Decrease/ (Increase) in Intangible Assets	(0.39)	(0.36)
	Decrease/ (Increase) in Financial Assets	(134.84)	(0.18)
	Decrease/(Increase) in Other Non Current Assets	2.88	(14.45)
	Decrease/ (Increase) in Non Current Investment	(262.60)	
	Interest Received	56.33	0.93
	Net Cash Inflow / (Outflow) from Investing Activities	**(424.91)**	**(48.01)**
C	**Cash Flow from Financing Activities**		
	Proceeds/(repayment) of short term borrowings (net)	(277.40)	(231.23)
	Proceeds/(repayment) of long term borrowings (net)	(40.12)	52.38
	Finance cost	(60.82)	(46.31)
	Proceeds from issue of equity shares	-	51.45
	Proceeds from security premium on issue of shares	(20.73)	1,000.94
	Proceeds/(repayment) of other financial liability	(2.86)	14.24
	Net Cash Inflow / (Out Flow) from Financing Activities	**(401.93)**	**841.47**
	Net Increase/(Decrease) in Cash & Cash equivalents	(2,866.33)	133.34
	Cash and Cash Equivalents at the Beginning	4,102.81	20.86
	Cash and Cash Equivalents at the End	1,236.49	154.21

Date : 01-11-2026

Place : Hyderabad

For Sai Parenteral's Limited

SAI PARENTERALS LIMITED HYDERABAD

(Anil Kumar Karusala)
Chairman
DIN: 01866646

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY PERSUANT TO THE REGULATION 33 AND 52 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATION 2015

To
The Board of Directors
SAI PARENTERAL'S LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Sai Parenteral's Limited ("the Company" or "the Holding Company") and its subsidiary (together referred to as "the group"), for the quarter ended 30th September, 2026 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("IND AS 34"), "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the master Circular No. CIR/CFD/CMD1 /44/2019 dated March 29, 2019, issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

5. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

6. The statement includes the financial results of newly acquired entity i.e. Prathyak Laboratories Private Limited (60%) along with other subsidiaries whose interim financial results for the quarter ended 30th September, 2026, which have been reviewed by the other auditor Revat Laboratories Private Limited, whose reports have been furnished to us by the Management and our conclusion on the statement, in so far as it relates to the amount and disclosures included in respect of that subsidiary is based solely on the reports of the other auditor and procedures performed by other auditor with respect to the subsidiary and in addition to that procedures are performed as stated in paragraph 3 above.

7. Based on our review conducted as above and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Listing including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R Kabra & Co. LLP
Chartered Accountants
Firm Registration No. 104502W/W100721

Prakash Tekwani
Partner
Membership No.: 108681
UDIN: 26108681WTNMEM4383

Place: Hyderabad
Date: 01/11/2026

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS OF THE COMPANY PERSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGUALTION 2015

To
The Board of Directors
Sai Parenteral's Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sai Parenteral's Limited ("the Company") for the quarter ended 30th September 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), consequent to the listing of the equity shares of the Company on the Stock Exchange.

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("Ind AS") 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. The Statement has been prepared in compliance with the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R Kabra & Co. LLP
Chartered Accountants
Firm Registration No:104502W/W100721

Prakash Tekwani
(Partner)
Membership No: 108681
UDIN:26108681UYDXSB8465

R KABRA & CO. LLP
904, Sarap Complex,
Opp. Navjivan Press,
C.U. Shah College Road,
Ashram Road,
Ahmedabad-380 009
CHARTERED ACCOUNTANTS

Place: Hyderabad
Dated: 01/11/2026